Is angiotensin-converting enzyme inhibitor a contraindication for contrast-induced nephropathy prophylaxis? A review...

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Contrast-induced nephropathy (CIN) is a leading cause of hospital-acquired acute renal failure.
• The use of angiotensin-converting enzyme (ACE) inhibitors in patients undergoing procedures involving contrast media is common but controversial.
• Existing literature presents conflicting evidence regarding the protective or detrimental effects of ACE inhibitors on CIN.

Purpose of the Study:

• To review the existing medical literature on the pathogenesis of CIN.
• To elucidate the role of the renin-angiotensin-aldosterone system (RAAS) in the development of CIN.
• To discuss the effects of ACE inhibitors on CIN prevention and risk.

Main Methods:

• Literature review of studies investigating CIN.
• Analysis of the pathophysiological mechanisms of CIN.
• Examination of the impact of ACE inhibitors on renal hemodynamics and tubular function in the context of CIN.

Main Results:

• CIN pathogenesis involves medullary hypoxia from reduced renal blood flow and direct contrast medium toxicity.
• The activated RAAS, endothelin-1, and reactive oxygen species are implicated in CIN development.
• ACE inhibitors may counteract these detrimental pathways, but their net effect on CIN remains debated, particularly in renally impaired patients.

Conclusions:

• ACE inhibitors' role in CIN is complex and requires further investigation.
• Understanding the interplay between RAAS and CIN is crucial for optimizing patient management.
• Clinical practice regarding ACE inhibitor use before contrast procedures warrants careful consideration of potential risks and benefits.